Last updated on September 2018

HuMax-AXL-ADC Safety Study in Patients With Solid Tumors


Brief description of study

The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors

Detailed Study Description

The trial consists of two parts; a dose escalation part (phase I, first in- human (FIH)) and an expansion part (phase IIa).

The dose escalation part has two dose escalation arms: the first arm investigates a once every 3 weeks (1Q3W) dosing schedule and the second arm investigates a three administrations over 4 weeks (3Q4W) dosing schedule.

The Expansion part of the trial will further explore the recommended phase 2 dose and dosing regimens of HuMax-AXL-ADC as determined in Part 1

Clinical Study Identifier: NCT02988817

Contact Investigators or Research Sites near you

Start Over

Andre Johan Gelderblom, MD

Leiden University Medical Centre
Leiden, Netherlands
9.99miles
  Connect »